action cost end market show
sign life pharmachem still headwind
focu cut busi realign end market greenshoot see
ash result enough keep bull thesi move right direct
clear cost option real new ceo novo intent delay
action ii recent weak appear driven primarili terribl pharmachem result
macro headwind systemat share loss iii certain asi end-market
show modest improv bottom line investor patienc like well
reward lt adjust ep est
respect tp remain cse valuat still
risk macro headwind ii lack execut iii coronaviru iv fx
new year new strategi new episod focu control destini
short order ceo novo appear reinvigor asi move function
busi led structur ii shift decis make account busi unit
iii realign incent comp tie business-unit perform action along
highli probabl materi cost-cut measur renew focu innov
debt restructur effort bolster ash profit begin
latter took substanti measur januari restructur debt result
improv debt-matur profil ii diversifi sourc capit eur bond issuanc
iii reduct annual cash interest expens cse
fy run-rat encourag initi action implement ceo novo
remain confid ash abil meaning improv asi margin
pharmachem wors weak expect remov custom manufactur
clear littl justif model materi improv pharmachem
particular custom manufactur biz sale sens
custom question model complet biz loss per qtr
next qtr coupl headwind w/ closur effect legaci seg due
custom destock cse rev per qtr arriv hit per
quarter albeit lower segment margin cse result per qtr
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
ashland busi consist three segment ashland specialti
ingredi composit intermedi solvent
scenario assum success re-segment asi
materi cost reduct return top-lin growth
impli ebitda discount back impli
grey scenario assum continu macro headwind
pharmachem weak lacklust cost improv
top-lin growth impli ebitda
 close
asi weak moder ex-pharmachem macro headwind abat
view core asi weak reflect prev announc oral loss gantrez
etc iii custom inventori action pharma pc hair etc wont argu
nt weak isnt concern note consist competitor custom
gener macro commentari werent sever justifi concern
pharmachem loss sincer doubt investor would bearish asi outlook
howev junctur believ yet evid true non-
macro issu fact limit pharmachem oral latter recent show
improv believ probabl revenu growth rate demonstr
better particip among asi key segment deriv optim custom
inventori level pharma pc modest improv key end market
residenti construct residenti re-paint help adhes former coat
latter still cautiou auto adhes construct
improv enough drive inflect
around asi world w/ credit suiss expect asi
life scienc expect lt growth price power osd pill market growth
potenti share gain w/ option add capac klucel virginia
 expand inject view inject one target
household
skin expect continu growth biofunct bioactiv plant extract
better penetr key custom us abroad still rel fragment
market natur ingredi opportun enhanc distribut exist
sun comp eas europ america due
signific weather headwind addit experi
fewer procur issu yr/yr due fewer trade headwind
oral show sign growth lower low new product introduct
fulli lap gantrez biz loss worst like optimist return growth
hair consist industri commentari see hair sluggish
interim due choppi macro believ also difficult comp
due recent product launch indic comp eas
coat architectur paint volum improv yr/yr drive posit
inflect coat volum enter recent commentari
asian paint nippon believ major custom
indic sound architectur paint volum also gain share
adhes auto oem build rate remain fairli weak least
us construct improv result healthier backlog
packag fairli stabl remain optimist adhes price/mix
compani mention price
christoph parkinson kieran de brun luca beaumont harri fein certifi respect compani secur
individu analyz view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori ashland global hold inc ash
signifi initi assumpt coverag
price rate histori asian paint aspn bo
signifi initi assumpt coverag
price rate histori compani shw
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well europea exclud turkey rate
base stock total return rel analyst coverag univers consist compani cover analyst within th relev sector
outperform repres attract neutral less attract underperform least att ractiv invest opportun latin america
turkey asia exclud japan australia stock rate base stock total return rel averag tal return relev countri
region benchmark india bse sensex index prior octob canadian rate base stock absolut total return
potenti current share price rel attract stock total return potenti within anali ts coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform
under-perform rate overlap neutral threshold oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close
